Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - Department of Tumor Biology

7 publications found

Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E (2021)
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Cancer Immunol Immunother (in press)
DOI 10.1007/s00262-021-02876-w, PubMed 33580363

Luna S, Torices L, Mingo J, Amo L, Rodríguez-Escudero I, Ruiz-Ibarlucea P, Erramuzpe A, Cortés JM, Tejada MI, Molina M, Nunes-Xavier CE, López JI, Cid VJ, Pulido R (2021)
A global analysis of the reconstitution of PTEN function by translational readthrough of PTEN pathogenic premature termination codons
Hum Mutat (in press)
DOI 10.1002/humu.24186, PubMed 33600059

Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
Proteomic analyses Identify Major Vault Protein as a Prognostic Biomarker for Fatal Prostate Cancer
Carcinogenesis (in press)
DOI 10.1093/carcin/bgab015, PubMed 33609362

Solis N, Zavaleta E, Wernhoff P, Dominguez-Barrera C, Dominguez-Valentin M (2021)
Challenges to Bringing Personalized Medicine to a Low-Resource Setting in Peru
Int J Environ Res Public Health, 18 (4)
DOI 10.3390/ijerph18041470, PubMed 33557277

Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA, Hereditary Breast Cancer Clinical Study Group (2021)
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
Breast Cancer Res Treat
DOI 10.1007/s10549-020-06072-9, PubMed 33423179

Torices L, de Las Heras J, Arango-Lasprilla JC, Cortés JM, Nunes-Xavier CE, Pulido R (2021)
MMADHC premature termination codons in the pathogenesis of cobalamin D disorder: Potential of translational readthrough reconstitution
Mol Genet Metab Rep, 26, 100710
DOI 10.1016/j.ymgmr.2021.100710, PubMed 33552904

Valsalakumari R, Yadava SK, Szwed M, Pandya AD, Mælandsmo GM, Torgersen ML, Iversen TG, Skotland T, Sandvig K, Giri J (2021)
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
Int J Pharm, 597, 120217 (in press)
DOI 10.1016/j.ijpharm.2021.120217, PubMed 33486035

 
Page visits: 531863